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Cardioprotection by rosiglitazone against ischemia-reperfusion involves upregulation of
AT2 and downregulation of AT1 receptors. P42/44 MAPK is also inhibited by rosiglita-
zone. Insulin signaling is not involved in cardioprotection by rosiglitazone.
11:45 a.m.
883-6 Carbon Monoxide Protects Against Cardiac Ischemia-
Reperfusion Injury In Vivo Through Mitogen-Activated 
Protein Kinanse Pathway and Akt-Endothelial Nitric 
Oxide Synthase Pathway
Hajime Fujimoto, Seiji Ayabe, Nobukazu Ishizaka, Minoru Ohno, Ryozo Nagai, University 
of Tokyo, Tokyo, Japan
Background: Heme oxygenase-1 (HO-1) is an endogenous anti-stress enzyme that
catabolizes heme to free iron, carbon monoxide (CO), and biliverdin. Recently, CO is
postulated to play a protective role against tissue injury induced by several stresses. In
this study, we investigated the role of CO in amelioration of cardiac ischemia-reperfusion
injury, and the mechanism involved in it. Methods and Results: Rats inhaled CO (250
ppm, 500 ppm, or 1000 ppm, balanced with air) or room air for 24 hr in a chamber. Then
the left anterior descending coronary artery was occluded for 30 min, followed by 120
min reperfusion, during which they continued inhaling CO or room air. CO had no effects
on body temperature or hemodynamic parameters before ischemia-reperfusion. Pre-
treatment with 1000 ppm of CO, but not 250 ppm nor 500 ppm, significantly reduced the
ratio of the infarct area to the risk area (I/R ratio; room air 35 ± 4 % vs. 1000 ppm CO 6 ±
2 %, P < 0.001), and suppressed the migration of macrophages and monocytes, and the
expression of tumor necrosis factor-a (TNF-a) in the risk areas (P < 0.05, those with 1000
ppm CO vs. without CO). Inhalation of 1000 ppm CO elevated HbCO up to 30% in blood.
Thus, tissue hypoxia–induced preconditioning is suspected to be responsible for this phe-
nomenon. However, the simple hypoxia (under 0.5 atom air for 24 hr) did not reduce I/R
ratio. CO activated MAPKs (p38, JNK, and ERK), Akt, and eNOS in the heart within 12
hours; although neither 250 ppm nor 500 ppm CO nor exposure to the simple hypoxia
activated them. Pre-treatment with SB203580, or wormannin completely blocked the acti-
vation of p38, or Akt and eNOS, respectively. They disturbed the cytoprotective effects of
CO additively (I/R ratio; 20 ± 3% (SB203580 + CO), 23 ± 2 % (wortmannin + CO), and 39
± 4 % (SB203580 + wortmannin + CO) vs. those with vehicle + CO; 9 ± 3 %, respectively,
P < 0.05). L-NAME (an inhibitor of NO production) also attenuated the tissue protection
by CO to almost to the same level as wortmannin (I/R ratio; 22 ± 5 % (L-NAME+CO)).
Conclusion: CO protects heart from ischemia-reperfusion injury. P38 pathway and Akt-
eNOS pathway are the key pathways in the cytoprotective effect of CO.
ORAL CONTRIBUTIONS
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10:45 a.m.
884-2 Cardiac Dysfunction in Non-ST Elevation ACS Is Partly 
Reversible: Analysis of Serial Measurements of NT-Pro 
B-Type Natriutetic Peptide
Bertil Lindahl, Nina Johnston, Tomas Jernberg, Matts Stridsberg, Per Venge, Lars 
Wallentin, The FRISK-II Study Group, University Hospital, Uppsala, Sweden
The inactive form of B-type Natriuretic Peptide, NT-proBNP, is a marker of acute as well
of chronic cardiac dysfunction. NT-proBNP is markedly elevated in acute nonSTE-ACS
and elevated levels are associated with an increased short- and long-term mortality.
However, little is known about the temporal changes of NT-proBNP and their causes after
an episode of nonSTE-ACS.
Methods: NT-proBNP was measured at inclusion in the study, after 6 weeks, 3 and 6
months together with Troponin T and C-Reactive Protein at inclusion in 642 patients
included in the FRISC-II invasive trial. The association between changes of NT-proBNP
over time and a number of clinical and laboratory parameters was evaluated by multiple
linear regression analysis.
Results: The NT-proBNP level decreased in median 172 ng/L (25th-75th perc.; 2-671)
from inclusion to 6 months. There was no significant statistically change in patients with-
out any myocardial damage (tnT <0.01 µg/L). In patients with myocardial damage (tnT
>0.01 µg/L) higher levels of tnT and CRP were associated with a larger decrease in NT-
proBNP, whereas higher weight, a history of diabetes, smoking and chronic heart failure,
respectively, were associated with increasing NT-proBNP levels.
Conclusion: Cardiac dysfunction, as measured by NT-proBNP, is to a large extent
reversible in nonSTE-ACS patients. Reversible dysfunction is associated with tnT and
CRP elevation. Irreversible dysfunction is associated with diabetes, chronic heart failure,
smoking and weight. 
11:00 a.m.
884-3 Clinical Implications of Discordant Creatine Kinase-MB 
and Troponin Results in Patients With Acute Coronary 
Syndromes
L. Kristin Newby, Eric D. Peterson, Anita Chen, Robert A. Harrington, Charles V. Pollack, 
Jr., James W. Hoekstra, Robert H. Christenson, Robert L. Jesse, W. Brian Gibler, E. 
Magnus Ohman, Matthew T. Roe, Duke Clinical Research Institute, Durham, NC, 
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Creatine kinase-MB (CKMB) and cardiac troponins (Tn) are often mea-
sured concurrently in patients with non–ST-segment elevation acute coronary syndromes
(NSTE ACS). The significance of discordant CK-MB and Tn results remains controversial
and their effect on ACS care delivery is unknown.
Methods: Among 29,357 NSTE ACS patients in the CRUSADE Initiative who had both
CKMB and Tn measured during the first 36 hours, we examined relationships of 4 combi-
nations of marker results (CKMB-/Tn-, CKMB+/Tn-, CKMB-/Tn+, CKMB+/Tn+) with clini-
cal outcomes and use of ACC/AHA guidelines-recommended acute management
strategies. (Markers considered + if above upper limit of normal.)
Results: 28% had discordant CKMB and Tn results (10% CKMB+/Tn-; 18% CKMB-/
Tn+). Results are shown in the Table. Patterns were similar after excluding patients with
renal insufficiency.
Conclusions: Mortality in Tn+ patients is increased regardless of CKMB status, but
CKMB elevation in the absence of elevated Tn does not predict increased mortality. Par-
adoxically, use of GPIIb-IIIa and early invasive strategies among Tn+ patients appears
biased by CKMB results despite this risk pattern and that the bulk of evidence for use is
based on Tn+ status. Recognition of these risk differences may contribute to more appro-
priate early use of antiplatelet therapy and early invasive management strategies for all
Tn+ patients. 
11:15 a.m.
884-4 Higher Levels of Thrombus Precursor Protein Are 
Associated With Increased Death and Ischemic 
Complications in Patients With Acute Coronary 
Syndromes
Jessica L. Mega, Marc S. Sabatine, David A. Morrow, James A. de Lemos, Sabina A. 
Murphy, Carolyn H. McCabe, Christopher P. Cannon, Eugene Braunwald, TIMI Study 
Group, Brigham and Women's Hospital, Boston, MA
Background: Thrombus Precursor Protein (TpP), which measures soluble fibrin, is a
marker of active thrombosis. We evaluated the relationship between TpP and clinical out-
comes in patients with acute coronary syndromes (ACS).
Methods: Baseline TpP levels were measured in 2349 patients with ACS enrolled in
OPUS-TIMI 16. Death, nonfatal MI, recurrent ischemia requiring urgent revascularization
(Urg Revasc), and severe ischemia leading to rehospitalization (Sev Isch) were evaluated
Use of guideline-recommended acute treatment strategies (medications given within 24 
hours) and clinical outcome by marker category
CKMB-/Tn-
(n=3,502)
CKMB+/Tn-
(n=2,988)
CKMB-/Tn+
(n=5,349)
CKMB+/Tn+
(n=17,518)
Aspirin (%) 89 91 91 92
B-blocker (%) 70 70 76 79
Heparin (%) 71 72 76 87
GP IIb-IIIa (%) 18 24 23 38
Cath <48 hrs (%) 39 36 35 45
PCI (%) 31 31 29 36
In-hospital death (%) 2.71 2.95 4.45 5.87
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through 10 months.
Results: Median TpP levels were 8.9 ug/ml (IQR 4.8-15.9). Higher baseline levels of TpP
were associated with older age, hypertension, diabetes, prior CAD, and prior CHF
(p<0.05 for each). TpP levels correlated only weakly with troponin I (TnI), C-reactive pro-
tein (CRP), and B-type natriuretic peptide (BNP) (|r|<0.1 for each). The risk of death, MI,
Urg Revasc, Sev Isch, and the composite increased progressively with rising levels of
TpP (Fig). After adjusting for baseline differences, including TnI, CRP, and BNP, patients
with TpP levels above the median remained at significantly increased risk for the com-
posite endpoint (hazard ratio 1.47, p=0.001).
Conclusion: In patients with ACS, elevated levels of TpP at baseline are associated with
an increased risk of death and ischemic complications. These data support the value of
combining a marker of active thrombosis, such as TpP, with established biomarkers of
necrosis, inflammation, and hemodynamic stress for risk assessment in ACS.
11:30 a.m.
884-5 Impact of Troponin Status and Coronary Artery Disease 
by Angiography on Outcome in Acute Coronary 
Syndrome: A TACTICS TIMI-18 Substudy
Manu Pillai, Peter DiBattiste, Sabina Murphy, David Morrow, Christopher Cannon, Nasser 
M. Lakkis, Baylor College of Medicine, Houston, TX, Brigham and Women's Hospital, 
Boston, MA
Background: Cardiac troponin (Tn) T and I elevations are powerful independent prog-
nostic indicators in the setting of acute coronary syndrome (ACS). However, in clinical
practice, seemingly “false positive” Tn's are common . Methods and Results: To evalu-
ate whether such patients are “false positives” and if there is clinical significance of an
elevated Tn, we evaluated the prognosis of ACS patients enrolled in TACTICS-TIMI-18
study according to the presence or absence of CAD on angiography and Tn status on
admission. In this study 1,372 patients underwent angiography. A subset of 455 patients
were Tn negative, and of those, 362 (79.6%) had significant CAD (>50%stenosis in one
or more vessel). Fifty-seven out of 917 patients (6.2%) with + TnT or I did not have signif-
icant CAD. The mean value of TnT in patients with angiographic CAD was 0.603 ng/ml
compared to 0.281 ng/ml in those without CAD (p=0.01). The mean value of TnI was 9.39
ng/ml in patients with CAD compared to 3.32 ng/ml ( in patients without CAD (p=0.005).
An outcome of death or reinfarction at 6 months is shown in table.
o:p> 
Conclusions: Elevated troponin in ACS confers a significantly high risk for death or MI,
even among patients who are found to not have significant CAD. The mechanism of this
adverse outcome deserves further study, but these data suggest that all patients present-
ing with a clinical history of ACS and a positive troponin at presentation deserve early
and long-term aggressive preventive management.
11:45 a.m.
884-6 Incidence of Vulnerable Plaques in Humans: 
Assessment With 3-D Intravascular Palpography
Johannes A. Schaar, Evelyn Regar, Francesco Saia, Chris L. de Korte, Frits Mastik, 
Anton F. van der Steen, Patrick W. Serruys, Erasmus Medical Center, Rotterdam, The 
Netherlands, Interuniversity Cardiology Institute of the Netherlands, Utrecht, The 
Netherlands
Intravascular palpography (IP) can detect deformable thin-cap fibroatheroma with a high
sensitivity and specificity by measuring the strain of the plaque surface. These vulnerable
plaques show a typical high strain pattern. We hypothesized that it is possible to detect
vulnerable plaques in-vivo in human coronary arteries by scanning the coronary artery
for typical high strain patterns.
Method: IP was performed in 56 patients by using standard 20 MHz intravascular ultra-
sound catheters (Avanar, JOMED Inc). Analysis included the complete length of the ves-
sel. The population was divided into 3 groups: Patients with [1] antecedent (<24h)
myocardial infarction. (post MI) [2] unstable angina (ST depression, Troponin negative);
(unstable). [3] Stable angina (stable). Per patient one coronary artery was investigated.
Results: IP was successful performed in all patients. The number of typical strain pat-
terns reflecting the number of vulnerable plaques per coronary artery are given in the
table. There was a significant difference between the stable vs. unstable group (p<0.001)
and stable vs. post MI group (p<0.0001). No difference was seen between the unstable
group and post MI group (p<0.056). 
Conclusion:
IP can be used to assess the number vulnerable plaques in humans. This pilot study
revealed a clear association between clinical presentation and the amount of vulnerable
plaques. Additional validation has to be performed to assess the predictive value of the
technique to identify vulnerable patients.
ORAL CONTRIBUTIONS
891 
Enhanced Extracorporeal 
Counterpulsation: Mechanisms and 
Clinical Results
Wednesday, March 10, 2004, 10:30 a.m.-Noon
Morial Convention Center, Room 257
10:30 a.m.
891-1 Enhanced External Counterpulsation Decreases Wave 
Reflection Amplitude and Reduces Left Ventricular 
Afterload and Systolic Stress in Patients With 
Refractory Angina
Wilmer W. Nichols, Randy W. Braith, Rahul Aggarwal, C. R. Conti, University of Florida, 
Gainesville, FL
Background: Myocardial ischemia is associated with increased arterial stiffness which
causes early return of reflected pressure waves from the lower body and augments aortic
systolic and pulse pressures and increases left ventricular afterload and myocardial oxy-
gen demand. The aim of this study was to determine if arterial properties and wave
reflection characteristics are altered after EECP treatment in patients with chronic stable
angina resistant to anti-anginal medication. Methods: High-fidelity radial artery pressure
waveforms were recorded non-invasively by applanation tonometry and ascending aortic
pressure waveforms generated using a mathematical transfer function. Twenty patients
(age 61±7.3 years) with refractory angina taking two or more anti-anginal drugs were
studied. Data were collected before and after 34 one-hour EECP sessions. Augmentation
index (AIa, index of aortic stiffness) and amplitude and timing of the reflected pressure
wave (index of myocardial oxygen demand) were calculated from the generated aortic
pressure waveform. Results: EECP caused a significant decline in AIa from 27±10 to
19±9.8% (p<0.02) and a delay in reflected wave travel time from 68±8.3 to 74±6.8 msec
(p<0.01). These modifications in wave reflection characteristics were associated with a
decline in reflected wave amplitude (from 13±7.2 to 9.0±7.0 mm Hg, p<0.01) and dura-
tion (from 189±34 to 174±40 msec, p<0.01) which caused a decrease in aortic systolic
(from 120±18 to 108±18 mm Hg, p<0.01) and pulse (from 48±15 to 41±16 mm
Hg,p<0.01) pressure. The average number of anginal episodes per week decreased from
7.1±6.0 to 1.1±1.2 (p<0.02) while heart rate, body weight and drug regimen did not
change during the course of the study. Conclusions: EECP treatment delays return of the
reflected pressure wave from the periphery to the heart, reduces its amplitude and,
therefore, decreases aortic blood pressure and systolic stress in patients with refractory
angina taking anti-anginal medication. These changes, which are likely due to decreased
arterial stiffness and pulse wave velocity of the muscular arteries in the legs, reduce myo-
cardial oxygen demand and decrease the number of anginal episodes.
10:45 a.m.
891-2 External Counterpulsation Therapy: Significant Clinical 
Improvement Without Electrophysiologic Remodeling
Charles A. Henrikson, Nisha Chandra-Strobos, Johns Hopkins Medical Institutions, 
Baltimore, MD
Background: External counterpulsation therapy (ECP) non-invasively improves coronary
flow, hemodynamics, and time to ischemia in patients with severe coronary artery dis-
ease (CAD). Other treatments with similar effects, e.g. left ventricular assist devices, pro-
mote electrophysiologic remodeling, with a narrowing of the QRS complex.
Methods: We studied 28 patients, who completed a 7 week 35 hour session of ECP, to
assess whether such therapy would also result in electrophysiological remodeling, espe-
cially if associated with clinical improvement. All patients had class II-III angina, imaging-
proven ischemia, and severe CAD.
Results: Of 28 patients, with mean age 62+/-13 years (mean +/-SD), 78% were male,
46% diabetic, 82% hypertensive, 60% had undergone angioplasty, and 67% bypass sur-
gery. The mean ejection fraction was 44% (range 25-60%). Following ECP, most patients
(82%) had at least a one full class improvement in their anginal pattern. In most patients,
there was substantial baseline conduction system disease present: a mean QRS of 105
+/- 19 msec. Of note, there was no significant change in heart rate, PR, QRS, or QTc
intervals before and after ECP in either clinical responders or non-responders. When
Tn neg,
no CAD
n=93
Tn pos
no CAD
n=57
Tn neg
CAD
n=362
Tn pos
CAD
n=860
p-value
Death 0% 1.75% 2.21% 4.07% 0.082
MI 0% 3.51% 4.42% 8.26% 0.003
death or MI 0% 5.26% 5.52% 11.16% <0.001
Stable Unstable Post MI
n (patients) 19 19 18
High strain spots 0.7 ± 0.5 1.7 ± 0.4 2.0 ± 0.8
